What a Fish Study Reveals About Psilocybin and Aggression

A small fish known for defending its territory is offering researchers a new way to investigate how psilocybin influences social behavior. After exposure to the psychedelic compound, mangrove rivulus fish moved less and made fewer aggressive lunges toward another fish.

The findings come from a study published in Frontiers in Behavioral Neuroscience by researchers affiliated with Acadia University, Université de Moncton, and the University of British Columbia.¹ They provide an interesting starting point for understanding behavioral effects that remain relatively understudied in psychedelic research.

The most useful question, however, goes beyond whether psilocybin made the fish less aggressive. Did it specifically change their response to a social challenge, or did they attack less because they were generally less active? Answering that question could help scientists distinguish a measurable drug effect from a potentially useful therapeutic mechanism.

How Researchers Tested Psilocybin and Fish Aggression

Mangrove rivulus, scientifically known as Kryptolebias marmoratus, are amphibious fish that naturally display aggression toward members of their own species. This makes them useful for studying how drugs influence confrontational behavior under controlled conditions.

The researchers observed focal fish alongside size-matched stimulus fish, separated by a mesh barrier. The divider allowed visual and chemical communication while preventing physical contact. Researchers could therefore record threatening displays and attempted attacks without allowing the animals to injure one another.

Each focal fish underwent a baseline observation. Twenty-four hours later, it received either a 20-minute psilocybin water bath or a control treatment before another social observation. The behavioral experiment included 16 focal fish in each treatment group, and recorded videos were analyzed without the observer knowing the treatment assignment.

The psilocybin bath contained 3,000 micrograms per litre. That number describes the surrounding water, not the amount absorbed by each fish, an important distinction when interpreting the experiment.

What Changed After Psilocybin Exposure?

Treated fish spent less time moving and performed fewer swimming bursts toward the fish across the barrier. These bursts were rapid, directed darts that researchers classified as aggressive attacks.

The differences were detectable against the control group, rather than simply reflecting a change from the treated animals’ own baseline. The analysis of behavioral changes indicated a large effect on movement and a medium effect on aggressive bursts.

Other results were less clear-cut. Psilocybin did not produce a distinct treatment effect on several measures, including head-on displays and overall interaction time. Some behaviors declined during the second observation in both groups, suggesting that repeated exposure to the social situation also mattered.

This pattern supports a focused conclusion: psilocybin altered particular behaviors under these experimental conditions. It does not establish that every aspect of aggression or social engagement was reduced.

Why Reduced Movement Does Not Automatically Mean Calm

A quieter animal may be less anxious, less motivated to fight, less able to move, or simply responding differently to its surroundings. Observing reduced activity alone cannot distinguish these possibilities.

The simultaneous decline in movement and attacking therefore creates an important interpretive challenge. If a fish swims less overall, fewer attacks may follow even without a specific change in aggression. The present study does not establish how much of the attack reduction can be explained by lower activity.

That uncertainty makes the next experiments more valuable. Researchers could examine attacks relative to movement, test responses outside a social confrontation, and measure whether normal exploration remains intact. A compound that selectively reduces aggressive reactions would have a different behavioral profile from one that broadly suppresses activity.

The clinical implication is straightforward: useful treatment should support functioning. Fewer outward signs of distress are encouraging only when they accompany meaningful improvements in the individual’s condition.

Why Genetically Similar Fish Responded Differently

Mangrove rivulus have another unusual feature: they can reproduce through self-fertilization. After many generations, laboratory lineages contain individuals with highly similar genetic backgrounds, helping researchers reduce one source of experimental variation.

Nevertheless, fish within the same lineage showed considerable differences in their behavioral responses. The authors discuss possible contributions from physiological state, epigenetic differences, and individual behavioral traits.

This finding does not show that genetics is irrelevant. The behavioral experiment used one lineage for focal fish, so it was not a comprehensive comparison of treatment responses across genetic backgrounds.

Its broader lesson is that genetic similarity does not guarantee behavioral uniformity. For psychedelic research, that supports studying variation directly rather than treating an average response as a complete description of what a compound does.

What Fish Models Can Contribute to Psychedelic Medicine

Fish cannot report emotional relief, describe a meaningful experience, or explain how their relationships have changed. Their value lies in allowing researchers to investigate simpler, observable components of behavior under controlled conditions.

Psilocybin is converted into psilocin, which interacts with serotonin receptors. Because serotonin signaling operates across vertebrates, animal models can help scientists formulate questions about biological processes that may also matter in humans. Shared biology provides a research opportunity, although it does not make species interchangeable.

Human research also highlights the importance of context. A 2026 Nature study examining psychedelics and brain responses to context investigated psilocybin under different conditions, including music and meditation. This illustrates why a drug’s effects should be studied alongside the circumstances in which it is experienced.

MyCannabis has similarly explored whether the psychedelic experience may be part of the medicine. Fish experiments can illuminate observable biological responses, while human studies must also address experience, interpretation, and lasting changes in daily life.

Why This Is Not Evidence for Human Microdosing

The researchers measured psilocybin and psilocin in whole-fish extracts to confirm absorption. These measurements used a different lineage from the behavioral experiment and showed increasing concentrations with higher waterborne exposures.

The authors compared the resulting low tissue concentration with published human plasma concentrations. However, a whole-body fish measurement and a human blood measurement represent different biological samples. Similar numerical values do not establish equivalent dosing, brain exposure, or subjective effects.

Consequently, the experiment cannot identify a human microdose or demonstrate that a particular dose would reduce aggression in people.

The timing also requires care. The 24-hour interval separated the baseline and treatment sessions. It does not mean that the behavioral effects lasted for 24 hours. Establishing durability would require observations at later time points after administration.

Connecting Behavioral Findings With Human Outcomes

Clinical studies provide a separate and more direct route to evaluating therapeutic benefit. An August 2026 randomized trial of psilocybin-assisted therapy for treatment-resistant depression enrolled 60 adults in an English National Health Service setting. It reported improvements in depressive symptoms with psilocybin and psychological support, supporting a larger confirmatory trial.

That research does not validate psilocybin as an aggression treatment. It demonstrates why the evidence must be matched to the question: a depression trial evaluates depression, while a fish experiment measures specific animal behaviors.

MyCannabis’s recent coverage of psilocybin and mindfulness for depression adds another useful distinction. An early change may help initiate recovery, but maintaining benefits can involve skills and support beyond the dosing session.

The Next Step Is More Precise Research

The rivulus study offers a practical foundation for follow-up work. The most informative experiments would examine:

• Whether reduced attacking remains after accounting for lower movement.
• How responses change across doses, genetic lineages, and social settings.
• Whether behavioral effects persist after the immediate exposure period.

These questions could clarify whether psilocybin changes aggressive motivation, general activity, or several processes at once. Adding measures of stress physiology and testing relevant receptor mechanisms would also help connect observed behavior with its biological causes.

The encouraging contribution is a workable model for asking better questions. Psilocybin produced measurable changes in a naturally aggressive species, while the mixed results reveal where interpretation needs greater precision. That combination can move psychedelic research toward a more useful goal: understanding which effects matter, for whom, and under what conditions.

References:

¹ Forsyth, D., Faraone, N., Lamarre, S. G., & Currie, S. (2026). The magic of mushrooms: Psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus. Frontiers in Behavioral Neuroscience, 20, Article 1767175. https://doi.org/10.3389/fnbeh.2026.1767175